Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Feasibility and Safety Study of Fluorescein-Specific (FITC-Ew) CAR T Cells in Combination with Parenterally Administered Folate-Fluorescein (UB-TT170) for Osteogenic Sarcoma

Next Previous
Trial Profile

A Phase I Feasibility and Safety Study of Fluorescein-Specific (FITC-Ew) CAR T Cells in Combination with Parenterally Administered Folate-Fluorescein (UB-TT170) for Osteogenic Sarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UB TT170 (Primary) ; CAR-T cell therapies
  • Indications Osteosarcoma
  • Focus Adverse reactions
  • Acronyms ENLIGHTen; ENLIGHten-01

Most Recent Events

  • 05 Jun 2025 Planned End Date changed from 30 Apr 2040 to 1 May 2040.
  • 07 Nov 2024 Status changed from recruiting to active, no longer recruiting.
  • 04 Oct 2024 According to an Umoja Biopharma media release, Company will be presenting early experience data from the ENLIGHTen-01 trial of UB-TT170 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on Friday, November 8, 2024 in Houston, Texas.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top